U.S. Lipitor Ruling May Affect Investor Reaction to Nexium Challenge

Drug Industry Daily
KEYWORDS Lawsuit / Patents
A A

An upcoming U.S. patent ruling on Lipitor could affect how investors react to a bid to market a generic version of AstraZeneca’s ulcer drug Nexium, according to one analyst.

To View This Article:

Login

Subscribe To Drug Industry Daily